Kidney Transplantation From Hepatitis-C Viraemic Donors:Considerations for Practice in the United Kingdom
- PMID: 35592447
- PMCID: PMC9110637
- DOI: 10.3389/ti.2022.10277
Kidney Transplantation From Hepatitis-C Viraemic Donors:Considerations for Practice in the United Kingdom
Abstract
Background: Donor hepatitis-C (HCV) infection has historically represented a barrier to kidney transplantation (KT). However, direct-acting antiviral (DAA) medications have revolutionised treatment of chronic HCV infection. Recent American studies have demonstrated that DAA regimes can be used safely peri-operatively in KT to mitigate HCV transmission risk. Methods: To formulate this narrative review, a comprehensive literature search was performed to analyse results of existing clinical trials examining KT from HCV-positive donors to HCV-negative recipients with peri-operative DAA regimes. Results: 13 studies were reviewed (11 single centre, four retrospective). Outcomes for 315 recipients were available across these studies. A sustained virological response at 12 weeks (SVR12) of 100% was achieved in 11 studies. One study employed an ultra-short DAA regime and achieved an SVR12 of 98%, while another achieved SVR12 of 96% due to treatment of a missed mixed genotype. Conclusion: HCV+ KT is safe and may allow increased utilisation of organs for transplantation from HCV+ donors, who often have other favourable characteristics for successful donation. Findings from US clinical trials can be applied to the United Kingdom transplant framework to improve organ utilisation as suggested by the NHSBT vision strategy "Organ Donation and Transplantation 2030: meeting the need".
Keywords: donor; hepatitis C infection; kidney transplant; utilisation; viraemia.
Copyright © 2022 Doherty, Athwal, Moinuddin, Augustine, Prince, van Dellen and Khambalia.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
-
- Pereira BJG, Milford EL, Kirkman RL, Levey AS. Transmission of Hepatitis C Virus by Organ Transplantation. [cited 2021 Jan 27]. N Engl J Med (1991) 325(7):454–60. 10.1056/NEJM199108153250702 Available from: https://www.nejm.org/doi/full/10.1056/NEJM199108153250702 . - DOI - DOI - PubMed
-
- Magnone M, Holley JL, Shapiro R, Scantlebury V, McCauley J, Jordan M, et al. Interferon - α - Induced Acute Renal Allograft Rejection. [cited 2021 Aug 5]. Transplantation (1995) 59(7):1068–70. 10.1097/00007890-199504150-00030 Available from: https://europepmc.org/articles/PMC2962569 . - DOI - PMC - PubMed
-
- Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, et al. Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection. [cited 2021 Jan 27]. N Engl J Med (2014) 370(20):1889–98. 10.1056/NEJMoa1402454 Available from: https://www.nejm.org/doi/full/10.1056/NEJMoa1402454 . - DOI - DOI - PubMed
-
- Levitsky J, Formica RN, Bloom RD, Charlton M, Curry M, Friedewald J, et al. The American Society of Transplantation Consensus Conference on the Use of Hepatitis C Viremic Donors in Solid Organ Transplantation. [cited 2020 Oct 1]. Am J Transplant (2017) 17(11):2790–802. 10.1111/ajt.14381 - DOI - PubMed
-
- Rudd RA, Aleshire N, Zibbell JE, Matthew Gladden R. Increases in Drug and Opioid Overdose Deaths - United States, 2000-2014. [cited 2021 Jan 27]. Am J Transpl (2016) 16(4):1323–7. 10.1111/ajt.13776 Available from: https://onlinelibrary.wiley.com/doi/full/10.1111/ajt.13776 . - DOI - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
